Oct 15th 2012 - Edison Investment Research today published a report on Worldwide Healthcare Trust (WWH.L, LSE:WWH, LON:WWH) entitled "Continued Strong Performance". In summary, the report says:
Worldwide Healthcare Trust (WWH) is a UK-registered investment trust offering diversified exposure to both the pharmaceutical and biotech sectors. It has a strong, long track record and during the last 12 months has returned 26.3% and 26.2% in terms of share price total return and NAV total return respectively, outperforming its benchmark, the MSCI World Healthcare Index (sterling adjusted), which returned 21.5%. WWH provided 16% year-on-year dividend growth for 2012 (15.0p to 17.5p) while adding 4.3p to revenue reserves. Biotech and pharma valuations, when compared to their longer-term averages, remain at lows despite the recent uplift, suggesting further potential remains. In addition, the outlook for M&A remains positive as big pharma companies seek to replenish their product pipelines.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »